- Home
- PNNT vs ARVN Comparison
PNNT vs ARVN Comparison
Compare PNNT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNNT
- ARVN
- Stock Information
- Founded
- PNNT 2007
- ARVN 2015
- Country
- PNNT United States
- ARVN United States
- Employees
- PNNT N/A
- ARVN N/A
- Industry
- PNNT Finance: Consumer Services
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- PNNT Finance
- ARVN Health Care
- Exchange
- PNNT Nasdaq
- ARVN Nasdaq
- Market Cap
- PNNT 442.7M
- ARVN 456.2M
- IPO Year
- PNNT 2007
- ARVN 2018
- Fundamental
- Price
- PNNT $7.16
- ARVN $7.32
- Analyst Decision
- PNNT Sell
- ARVN Buy
- Analyst Count
- PNNT 4
- ARVN 22
- Target Price
- PNNT $6.33
- ARVN $20.21
- AVG Volume (30 Days)
- PNNT 497.3K
- ARVN 2.0M
- Earning Date
- PNNT 08-11-2025
- ARVN 08-06-2025
- Dividend Yield
- PNNT 13.43%
- ARVN N/A
- EPS Growth
- PNNT 21.65
- ARVN N/A
- EPS
- PNNT 0.80
- ARVN N/A
- Revenue
- PNNT $130,923,000.00
- ARVN $372,800,000.00
- Revenue This Year
- PNNT N/A
- ARVN $7.57
- Revenue Next Year
- PNNT N/A
- ARVN N/A
- P/E Ratio
- PNNT $8.97
- ARVN N/A
- Revenue Growth
- PNNT N/A
- ARVN 299.57
- 52 Week Low
- PNNT $5.72
- ARVN $5.90
- 52 Week High
- PNNT $7.53
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- PNNT 49.12
- ARVN 52.39
- Support Level
- PNNT $7.03
- ARVN $6.96
- Resistance Level
- PNNT $7.53
- ARVN $7.30
- Average True Range (ATR)
- PNNT 0.14
- ARVN 0.39
- MACD
- PNNT -0.03
- ARVN 0.06
- Stochastic Oscillator
- PNNT 26.60
- ARVN 71.19
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.